Kim, Sung-Bae
Dent, Rebecca
Im, Seock-Ah
Espié, Marc
Blau, Sibel
Tan, Antoinette R
Isakoff, Steven J
Oliveira, Mafalda
Saura, Cristina
Wongchenko, Matthew J
Kapp, Amy V
Chan, Wai Y
Singel, Stina M
Maslyar, Daniel J
Baselga, José
Kim, Sung-Bae
Lee, Keun Seok
Im, Seock-Ah
Espié, Marc
Wang, Hwei-Chung
Blau, Sibel
Dent, Rebecca
Tan, Antoinette
Sohn, Joo Hyuk
De Laurentiis, Michelino
Estevez, Laura Garcia
Huang, Chiun-Sheng
Romieu, Gilles
Velez, Michel
Villanueva, Rafael
Conte, Pier Franco
Dakhil, Shaker
Debled, Marc
Martin, Antonio Gonzalez
Hurvitz, Sara
Kim, Jee Hyun
Levy, Christelle
Oliveira, Mafalda
Rovira, Pedro Sanchez
Seo, Jae Hong
Valero, Vicente
Vidal, Gregory
Wong, Andrea
Allison, Mary Ann K
Figlin, Robert
Chan, David
Chen, Shin-Cheh
Chen, Yen-Hsun
Cobleigh, Melody
De Braud, Filippo
Dirix, Luc
Hansen, Vincent
Bessard, Anne Hardy
Iannotti, Nicholas
Isakoff, Steven
Lawler, William
Montaño, Alvaro
Salkini, Mohamad
Seigel, Leonard
This article is maintained by: Elsevier
Article Title: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(17)30450-3
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1470-2045(17)30514-4
Content Type: article
Copyright: © 2017 Elsevier Ltd. All rights reserved.